Release of SYBYL 6.9.1/UNITY 4.4.1 Includes Two New Discovery Technologies
ST. LOUIS, Sept. 8 /PRNewswire-FirstCall/ -- Tripos, Inc. (Nasdaq: TRPS),
a leading provider of drug discovery informatics products and chemistry
research, today announced the release of SYBYL(R) 6.9.1/UNITY(R) 4.4.1, the
latest version of its industry-leading computational chemistry platform for
drug design and discovery.
"Over the past 24 years, Tripos has provided cutting-edge research tools
to address the evolving needs of drug discovery programs," said Dr. Trevor
Heritage, senior vice president and general manager of discovery informatics
at Tripos. "These new technologies represent the latest enhancements to
Tripos' life sciences research products, further enhancing the breadth and
depth of the industry-leading SYBYL molecular modeling environment. Tripos
continues to provide proven innovative technologies along with outstanding
support to our computational customers. This latest release of SYBYL is a
demonstration of our continued commitment to computational chemistry as a
means of virtual discovery."
This software update features the addition of two major scientific
technologies, FUGUE(TM) and FlexX-Pharm(TM),* enhancing the SYBYL
computational platform in the following ways:
-- FUGUE is designed to assist in recognizing distant homologues
(divergent evolutionary relationships) by sequence-structure comparison.
This program provides structural and functional information about a
target sequence and a basis for comparative protein modeling.
FUGUE's key features are these:
-- Environment-specific substitution tables are improved.
-- The alignment algorithm is automatically selected with detailed
structure-dependent gap penalties. In addition, HOMSTRAD(TM), a
curated database of structure-based alignments for homologous
protein families, is used with FUGUE to find distantly related
proteins and generate accurate sequence- and structure-based
alignments for a sequence.
-- FlexX-Pharm adds functionality to FlexX(TM), enabling ligand-docking
calculations to be guided through interaction (i.e., pharmacophore
features) and spatial constraints. This new SYBYL module provides
virtual screening results that conform to a set of optional constraints
which can be utilized in the SYBYL module CScore(TM) for ligand
selection.
FlexX-Pharm's key features are these:
-- Before docking occurs, a quick prescreen can identify any ligands
that cannot satisfy the pharmacophore.
-- Hydrogen bonding, hydrophobic and metal interactions are defined
using FlexX interaction surfaces.
-- Spatial constraints enable spherical regions of space to be defined
in which a specific ligand atom (e.g., carbon, nitrogen, oxygen)
must be found.
-- Partial match directives can be defined in which a minimum and
maximum number of optional constraints must be satisfied in a valid
docking solution.
This software update also includes code release on multiple platforms.
Also available on Linux, SYBYL 6.9.1/UNITY 4.4.1 is the only complete
computational chemistry suite available that can be used with but does not
rely on mixed-platform or client-server architecture. Offering a diverse array
of solutions to support the ever-changing requirements of the computational
chemist, Tripos Discovery Informatics software is now available on three
platforms: Linux, SGI(R) and HP.
Tripos will be demonstrating its newly released SYBYL 6.9.1 modules,
FlexX-Pharm and FUGUE in Booth 303 at the American Chemical Society's 226th
National Meeting, being held at the Jacob K. Javits Convention Center in New
York City Sept. 8-10, 2003.
About Tripos, Inc.
Tripos (Nasdaq: TRPS) combines leading-edge technology and innovative
science to deliver consistently superior chemistry-research products and
services for the biotechnology, pharmaceutical and other life science
industries. Tripos partners with clients to accelerate and improve the
creation of life-enhancing products. Within Tripos' Discovery Informatics (DI)
business, the company provides software products and consulting services to
develop, manage, analyze and share critical drug discovery information. Within
Tripos' Discovery Research (DR) business, Tripos' medicinal chemists and
research scientists partner directly with clients in their research
initiatives, leveraging state-of-the-art information technologies and research
facilities. Headquartered in St. Louis, Mo., Tripos spans the world with
global research operations and an international client base. Further
information on Tripos can be found at http://www.tripos.com/.
* FlexX and FlexX-Pharm were developed by Dr. Sally Hindle and Prof. Dr.
Matthias Rarey and their colleagues at the former GMD institute SCAI
(now FhG) headed by Prof. Dr. Thomas Lengauer. BioSolveIT GmbH has
acquired exclusive rights to distribute, further develop, and maintain
FlexX and FlexX-Pharm.
This press release may contain certain statements that are forward-looking
and involve risk and uncertainties. Words such as "expects," "anticipates,"
"projects," "estimates," "intends," "plans," "believes," variations of such
words and similar expressions are intended to identify such forward-looking
statements. These statements are based on current expectations and projections
made by management and are not guarantees of future performance. Therefore,
actual events, outcomes and results may differ materially from what is
expressed or forecast in such forward-looking statements. We have identified
certain factors that could cause actual results to differ materially from the
forward-looking statements in our Annual Report on Form 10-K, our Quarterly
Reports on Form 10-Q, and our Current Reports on Form 8-K. Except as otherwise
required under federal securities laws and the rules and regulations of the
SEC, we do not have any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events, changes in assumptions or otherwise.
SOURCE Tripos, Inc.
 back to top
Related links:
http://www.tripos.com
CONTACT:
Jennifer McMahon, Director, Corporate
Communications of Tripos, Inc., +1-314-951-3367; or Lisa Osborne,
Account Supervisor of Waggener Edstrom Bioscience,
+1-425-638-7000 or lisao@wagged.com
|
